Pure Global

A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma - Trial NCT05805501

Access comprehensive clinical trial information for NCT05805501 through Pure Global AI's free database. This Phase 2 trial is sponsored by Hoffmann-La Roche and is currently Recruiting. The study focuses on Renal Cell Carcinoma. Target enrollment is 210 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT05805501
Phase 2
Recruiting
drug
Trial Details
ClinicalTrials.gov • NCT05805501
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
A Randomized Open Label Phase II Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

Study Focus

Renal Cell Carcinoma

RO7247669

Interventional

drug

Sponsor & Location

Hoffmann-La Roche

Fort Myers,Chattanooga,Knoxville,Nashville,Birtinya,Kurralta Park,Beijing City,Beijing,Nanjing City,Tianjin,Xi'an,Bordeaux,Caen,Lyon,Goyang-si,Jeollanam-do,Seoul,Seoul,Seoul,Bydgoszcz,Kraków,Pozna?,Ma, Australia,China,France,Poland,South Korea,Spain,United States of America

Timeline & Enrollment

Phase 2

Apr 21, 2023

Mar 31, 2026

210 participants

Primary Outcome

Progression-Free Survival (PFS)

Summary

This study will evaluate the efficacy, safety, and pharmacokinetics of RO7247669 (PD1-LAG3)
 in combination with axitinib alone or with tiragolumab (anti-TIGIT) and axitinib, as compared
 to pembrolizumab and axitinib in participants with previously untreated, unresectable locally
 advanced or metastatic clear-cell renal cell carcinoma (ccRCC).

ICD-10 Classifications

Malignant neoplasm of kidney, except renal pelvis
Malignant neoplasm of renal pelvis
Secondary malignant neoplasm of kidney and renal pelvis
Benign neoplasm: Kidney
Benign neoplasm: Renal pelvis

Data Source

ClinicalTrials.gov

NCT05805501

Non-Device Trial